The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The present invention provides modified sophorolipids of formula (I) that are more pH-and temperature-stable than its lactonic counterparts. Moreover, the compound has reduced HLB parameters, as well as improved wetting and solubilization parameters, water-in-oil emulsification ability, surface tension-lowering activity, and/or antimicrobial activity compared to their acidic or even lactonic counterparts.

The present invention provides modified sophorolipids of formula (I) that are more pH-and temperature-stable than its lactonic counterparts. Moreover, the compound has reduced HLB parameters, as well as improved wetting and solubilization parameters, water-in-oil emulsification ability, surface tension-lowering activity, and/or antimicrobial activity compared to their acidic or even lactonic counterparts.

The present disclosure provides methods for producing bioproducts from novel genetically altered strains of Aureobasidium pullulans. Methods and materials for the construction of these strains, examination of the bioproducts and analysis and isolation of the bioproducts from genetically altered strains is provided. Genetically altered A. pullulans strains in which one or more genes encoding biosynthetic enzymes are knocked out is detailed and the benefits of using such strains described.

A protein selected from the following (a) to (c), a gene encoding the protein, a transformant in which the gene is subjected to deletion, mutation or repression of gene expression, and a method of producing a glycolipid using the transformant are provided, wherein: (a) is a protein consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) is a protein consisting of an amino acid sequence having 50% or more identity with the amino acid sequence set forth in SEQ ID NO: 1, and having alcohol oxidase activity; and (c) is a protein consisting of an amino acid sequence in which one to several amino acids are subjected to deletion, substitution, insertion or addition in the amino acid sequence set forth in SEQ ID NO: 1, and having alcohol oxidase activity.

A protein selected from the following (a) to (c), a gene encoding the protein, a transformant in which the gene is subjected to deletion, mutation or repression of gene expression, and a method of producing a glycolipid using the transformant are provided, wherein: (a) is a protein consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) is a protein consisting of an amino acid sequence having 50% or more identity with the amino acid sequence set forth in SEQ ID NO: 1, and having alcohol oxidase activity; and (c) is a protein consisting of an amino acid sequence in which one to several amino acids are subjected to deletion, substitution, insertion or addition in the amino acid sequence set forth in SEQ ID NO: 1, and having alcohol oxidase activity.

The present disclosure relates generally to terpene glycosides, such as certain such compounds extracted from Stevia rebaudiana Bertoni, Rubus suavissimus, or Siraitia grosvenorii. The disclosure also provides for the use of such compounds as food ingredients, flavors, and sweeteners, and related methods. The disclosure also provides ingestible compositions comprising such compounds, as well as processes for extracting such compounds selectively from certain plant sources.

The present disclosure relates generally to terpene glycosides, such as certain such compounds extracted from Stevia rebaudiana Bertoni, Rubus suavissimus, or Siraitia grosvenorii. The disclosure also provides for the use of such compounds as food ingredients, flavors, and sweeteners, and related methods. The disclosure also provides ingestible compositions comprising such compounds, as well as processes for extracting such compounds selectively from certain plant sources.

Provided is a method for efficiently producing a monoacyl MEL. The method comprises culturing a monoacyl-MEL-producing microorganism in the presence of a surfactant.